RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF

Nature

Volumn 464, Issue 7287, 2010, Pages 427-430

  Poulikakos, Poulikos I ^a   Zhang, Chao ^b   Bollag, Gideon ^c   Shokat, Kevan M ^b   Rosen, Neal ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c PLEXXIKON INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATE; B RAF KINASE; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; PHOSPHOTRANSFERASE INHIBITOR; PLX 4032; PLX 4720; SORAFENIB; UNCLASSIFIED DRUG;

DRUG; ENZYME ACTIVITY; GENE EXPRESSION; MODEL TEST; MUTATION; TOXICITY; TUMOR;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BINDING SITE; CONTROLLED STUDY; DRUG BINDING; DRUG INHIBITION; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ADENOSINE TRIPHOSPHATE; ANIMALS; CATALYTIC DOMAIN; CELL LINE; CELL LINE, TUMOR; ENZYME ACTIVATION; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; HUMANS; INDOLES; MAP KINASE SIGNALING SYSTEM; MICE; MITOGEN-ACTIVATED PROTEIN KINASE KINASES; MODELS, BIOLOGICAL; NEOPLASMS; PHOSPHORYLATION; PROTEIN BINDING; PROTEIN KINASE INHIBITORS; PROTEIN MULTIMERIZATION; PROTO-ONCOGENE PROTEINS B-RAF; RAF KINASES; RAS PROTEINS; SULFONAMIDES; TRANSCRIPTIONAL ACTIVATION;

EID: 77949732073     PISSN: 00280836     EISSN: 14764687     Source Type: Journal    
DOI: 10.1038/nature08902     Document Type: Article

References (26)

1. Solit, D. B. et al. BRAF mutation predicts sensitivity to MEK inhibition. Nature 439, 358-362 (2006).
2. McDermott, U. et al. Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling. Proc. Natl Acad. Sci. USA 104, 19936-19941 (2007).
3. Wellbrock, C. et al. V599EB-RAF is an oncogene in melanocytes. Cancer Res. 64, 2338-2342 (2004).
4. Chapman, P. et al. Early efficacy signal demonstrated in advanced melanoma in a phase I trial of the oncogenic BRAF-selective inhibitor PLX4032. Eur. J. Cancer 7 (suppl.), 5 (2009).
5. Flaherty, K. et al. Phase I study of PLX4032: Proof of concept for V600E BRAF mutation as a therapeutic target in human cancer. J. Clin. Oncol. 27 (suppl.), abstr. 9000 (2009).
6. Tsai, J. et al. Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity. Proc. Natl Acad. Sci. USA 105, 3041-3046 (2008).
7. Wellbrock, C., Karasarides, M. & Marais, R. The RAF proteins take centre stage. Nature Rev. Mol. Cell Biol. 5, 875-885 (2004).
8. Young, A. et al. Ras signaling and therapies. Adv. Cancer Res. 102, 1-17 (2009).
9. Konecny, G. E. et al. Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells. Cancer Res. 66, 1630-1639 (2006).
10. Weber, C. K., Slupsky, J. R., Kalmes, H. A. & Rapp, U. R. Active Ras induces heterodimerization of cRaf and BRaf. Cancer Res. 61, 3595-3598 (2001).
11. Wan, P. T. et al. Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF. Cell 116, 855-867 (2004).
12. Rushworth, L. K., Hindley, A. D., O'Neill, E. & Kolch, W. Regulation and role of Raf-1/B-Raf heterodimerization. Mol. Cell. Biol. 26, 2262-2272 (2006).
13. Cutler, R. E. Jr, Stephens, R. M., Saracino, M. R. & Morrison, D. K. Autoregulation of the Raf-1 serine/threonine kinase. Proc. Natl Acad. Sci. USA 95, 9214-9219 (1998).
14. Okuzumi, T. et al. Inhibitor hijacking of Akt activation. Nature Chem. Biol. 5, 484-493 (2009).
15. Cameron, A. J., Escribano, C., Saurin, A. T., Kostelecky, B. & Parker, P. J. PKC maturation is promoted by nucleotide pocket occupation independently of intrinsic kinase activity. Nature Struct. Mol. Biol. 16, 624-630 (2009).
16. Karreth, F. A., DeNicola, G. M., Winter, S. P. & Tuveson, D. A. C-Raf inhibits MAPK activation and transformation by B-Raf(V600E). Mol. Cell 36, 477-486 (2009).
17. Blair, J. A. et al. Structure-guided development of affinity probes for tyrosine kinases using chemical genetics. Nature Chem. Biol. 3, 229-238 (2007).
18. Sun, Y. et al. Growth inhibition of nasopharyngeal carcinoma cells by EGF receptor tyrosine kinase inhibitors. Anticancer Res. 19, 919-924 (1999).
19. Rajakulendran, T., Sahmi, M., Lefrancois, M., Sicheri, F. & Therrien, M. A dimerization-dependent mechanism drives RAF catalytic activation. Nature 461, 542-545 (2009).
20. Hall-Jackson, C. A. et al. Paradoxical activation of Raf by a novel Raf inhibitor. Chem. Biol. 6, 559-568 (1999).
21. King, A. J. et al. Demonstration of a genetic therapeutic index for tumors expressing oncogenic BRAF by the kinase inhibitor SB-590885. Cancer Res. 66, 11100-11105 (2006).
22. Hoeflich, K. P. et al. Antitumor efficacy of the novel RAF inhibitor GDC-0879 is predicted by BRAFV600E mutational status and sustained extracellular signal-regulated kinase/mitogen-activated protein kinase pathway suppression. Cancer Res. 69, 3042-3051 (2009).
23. Heidorn, S. J. et al. Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF. Cell 140, 209-221 (2010).
24. Dummer, R. et al. AZD6244 (ARRY-142886) vs temozolomide (TMZ) in patients (pts) with advanced melanoma: An open-label, randomized, multicenter, phase II study. J. Clin. Oncol. 26 (suppl.), abstr. 9033 (2008).
25. Montagut, C. et al. Elevated CRAF as a potential mechanism of acquired resistance to BRAF inhibition in melanoma. Cancer Res. 68, 4853-4861 (2008).
26. Bankston, D. et al. A scaleable synthesis of BAY 43-9006: A potent Raf kinase inhibitor for the treatment of cancer. Org. Process Res. Dev. 6, 777-781 (2002).